MIV-150 is a nonnucleoside inhibitor of reverse transcriptase (NNRT). MIV-150 also blocking HIV-1 and HIV-2 infections (EC50<1 nM against HIV-1/HIV-2MN).

HIV-2:<1 nM (EC50), HIV-1:<1 nM (EC50)

MIV-150 potently inactivated free virus (EC50: 0.004 μg/mL (or 0.01 μM)). It is demonstrated MIV-150 is highly effective against HIV and that the drug blocks viruses that are resistant to other marketed HIV antiretrovirals such as Nevirapine, Delavirdine, and Efavirenz. Resistance to MIV-150 develops more slowly than other anti-HIV drugs tested. For example, in vitro studies demonstrate that resistance development in the presence of nevirapine and delavirdine takes only 4 to 5 weeks compared with 45 weeks in the presence of MIV-150. The activity of MIV-150 to protect target cells from infection is assayed using a syncytial assay. The EC50 of MIV-150 against HIV-1MN in CEM.SS cells is below 1 nM. These data are in agreement with the findings of Medivir .